Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 May 2025Published: 29 March 2023
Molnupiravir for treating COVID-19 (TA1056)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 April 2025
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023
Remdesivir for treating COVID-19 [ID3808]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ensitrelvir for treating COVID-19 [ID6231]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sabizabulin for treating COVID-19 [TSID11814]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vilobelimab for treating COVID-19 [TSID11815]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sipavibart for preventing COVID-19 [ID6282]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC